Concentraciones séricas de aminotransferasa y su asociación a la obesidad en pacientes hospitalizados por covid-19
Abstract
Los hallazgos científicos preliminares indican que los fenómenos relacionados con COVID-19, son graves en personas que padecen obesidad, dado que influye en los distintos cambios bioquímicos y sistemas del organismo. Es importante vislumbrar en profundidad el resultado que tiene la obesidad en el desarrollo y padecimiento de la COVID-19. El objetivo del estudio fue analizar la asociación entre las concentraciones séricas de aminotransferasas y la obesidad en pacientes hospitalizados por COVID-19. La investigación de diseño documental con carácter descriptivo y exploratorio el cual permitió seleccionar bajo criterios de inclusión 108 artículos publicados en los últimos años (2019-2022), relacionados al tema. Se evidenció una alta tasa de mortalidad en pacientes obesos con COVID-19 en comparación a sin obesidad, la prolongada estancia hospitalaria, oxigenoterapia, gravedad de la enfermedad, factor de riesgo sin restricción de edad, predisponen a casos graves e influyen en la peor progresión y el pronóstico. Los resultados clínicos, mostraron que las transaminasas, Fosfatasa Alcalina y Bilirrubina Total, tienden a permanecer en niveles altos en personas con obesidad. La evidencia sobre la severidad en pacientes obesos hospitalizados por COVID-19 indica gran variabilidad en la frecuencia de una mayor severidad asociada a la obesidad como factor de riesgo durante la COVID-19.
Downloads
Download data is not yet available.
References
1. Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, Batool R, Khalid M, Khan I, Iqbal N, Zaidi N. COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. PLoS One. 2021;16(8):e0255999. doi: 10.1371/journal.pone.0255999. PMID: 34379690; PMCID: PMC8357125.
2. Gargallo Vaamonde JG, Álvarez-Món MA. Obesidad y sobrepeso. Med - Programa Form Médica Contin Acreditado. 2020; 13(14):767–776. https://doi.org/10.1016/j.med.2020.07.010
3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
4. Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thursz MR, Nayagam S, Manousou P. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020; 15(10):e0240400. doi: 10.1371/journal.pone.0240400. PMID: 33031439; PMCID: PMC7544083.
5. Padilla Machaca PM, Cárdenas Ramírez BE, Cabrera Cabrejos MC. Impacto del COVID-19 en las enfermedades hepáticas y la salud pública en el Perú [Internet]. Vol. 40, Rev gastroenterol Peru. 2020; 40(2): 162–172. Available from: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1144655
6. López LE, Mazzucco MD. Alteraciones de parámetros de laboratorio en pacientes con SARS-CoV-2. Acta bioquímica clínica latinoamericana. 2020; Vol. 54 (3): 293–307. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-29572020000300006&lang=pt%0Ahttp://www.scielo.org.ar/pdf/abcl/v54n3/v54n3a06.pdf
7. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020; Vol. 40 (5): 998–1004. https://doi.org/10.1111/liv.14435
8. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63(3):364–374. https://doi.org/10.1007/s11427-020-1643-8
9. Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, Deng Y, Wei S. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(0):E005. Chinese. doi: 10.3760/cma.j.issn.1001-0939.2020.0005. PMID: 32026671.
10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507–513. https://doi.org/10.1016/s0140-6736(20)30211-7
11. Organización Mundial de la Salud/Organización Panamericana de la Salud. COVID-19 en Ecuador - OPS/OMS. 2021 [cited 2022 Apr 13]. Available from: https://www.paho.org/es/ecuador
12. Encuesta Nacional de Salud y Nutrición. 2018. Ecuador. La obesidad complica aún más los cuadros de pacientes con COVID-19. Estadisticas sociodemográficas. Disponible en: https://anda.inec.gob.ec/anda/index.php/catalog/891
13. Gonzalo Callejón MG, Caballero Villarraso J, Bobillo Lobato J, Díaz Portillo J. Contribuciones analíticas para el estudio de pacientes con infección COVID-19. Soc Andaluza Análisis Clínicos y Med Lab. 2020; (5):1–29. Disponible en: https://www.sanac.org/images/site/covid2019/2020_Callejon_y_cols_Contribuciones_analiticas.pdf
14. Nogueira-de Almeida CA, Del Ciampo LA, Ferraz IS, Del Ciampo IRL, Contini AA, Ued F da V. COVID-19 and obesity in childhood and adolescence: a clinical review. J Pediatr. 2020; Vol. 96: 546–558. https://doi.org/10.1016/j.jped.2020.07.001
15. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol. 2020; 18(7):1561-1566. doi: 10.1016/j.cgh.2020.04.002. PMID: 32283325; PMCID: PMC7194865.
16. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain M; LICORN and the Lille COVID-19 and Obesity study group. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity. 2020; 28(7):1195-1199. doi: 10.1002/oby.22831. Erratum in: Obesity (Silver Spring). 2020 Oct;28(10):1994. PMID: 32271993; PMCID: PMC7262326.
17. Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metab Syndr. 2020;14 (5):825-827. doi: 10.1016/j.dsx.2020.06.013. PMID: 32540736; PMCID: PMC7834636.
18. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, Mylonakis E. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity. 2020; 28(7):1200-1204. doi: 10.1002/oby.22859. PMID: 32352637; PMCID: PMC7267224.
19. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver Int. 2020; 40(6):1321-1326. doi: 10.1111/liv.14449. PMID: 32239591; PMCID: PMC7228333.
20. Deng M, Qi Y, Deng L, Wang H, Xu Y, Li Z, Meng Z, Tang J, Dai Z. Obesity as a Potential Predictor of Disease Severity in Young COVID-19 Patients: A Retrospective Study. Obesity. 2020; 28(10):1815-1825. doi: 10.1002/oby.22943. PMID: 32602202; PMCID: PMC7361308.
21. Chang TH, Chou CC, Chang LY. Effect of obesity and body mass index on coronavirus disease 2019 severity: A systematic review and meta-analysis. Obes Rev. 2020; 21(11):e13089. doi: 10.1111/obr.13089. PMID: 32929833.
22. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: A systematic review and meta-analysis. J Med Virol. 2021; 93(1):257-261. doi: 10.1002/jmv.26237. PMID: 32603481; PMCID: PMC7361606.
23. Perez A, Cantor A, Rudolph B, Miller J, Kogan-Liberman D, Gao Q, Da Silva B, Margolis KG, Ovchinsky N, Martinez M. Liver involvement in children with SARS-COV-2 infection: Two distinct clinical phenotypes caused by the same virus. Liver Int. 2021; 41(9):2068-2075. doi: 10.1111/liv.14887. PMID: 33826804; PMCID: PMC8251417.
24. Krishnan A, Prichett L, Tao X, Alqahtani SA, Hamilton JP, Mezey E, Strauss AT, Kim A, Potter JJ, Chen PH, Woreta TA. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World J Gastroenterol. 2022; 28(5):570-587. doi: 10.3748/wjg.v28.i5.570. PMID: 35316959; PMCID: PMC8905016.
25. Russo A, Pisaturo M, Palladino R, Maggi P, Numis FG, Gentile I, Et al. On Behalf Of CoviCam Group. Prognostic Value of Transaminases and Bilirubin Levels at Admission to Hospital on Disease Progression and Mortality in Patients with COVID-19- An Observational Retrospective Study. Pathogens. 2022;11(6):652. doi: 10.3390/pathogens11060652. PMID: 35745506; PMCID: PMC9227474.
26. Elnaggar M, Abomhya A, Elkhattib I, Dawoud N, Doshi R. COVID-19 and liver diseases, what we know so far. World J Clin Cases. 2022;10(13):3969-3980. doi: 10.12998/wjcc.v10.i13.3969. PMID: 35665122; PMCID: PMC9131221.
27. Siddiqui MA, Suresh S, Simmer S, Abu-Ghanimeh M, Karrick M, Nimri F, Musleh M, Mediratta V, Al-Shammari M, Russell S, Jou J, Dang D, Salgia R, Zuchelli T. Increased Morbidity and Mortality in COVID-19 Patients with Liver Injury. Dig Dis Sci. 2022; 67(6):2577-2583. doi: 10.1007/s10620-021-07007-0. PMID: 33945064; PMCID: PMC8094979.
28. Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases. 2022; 10(4):1140-1163. doi: 10.12998/wjcc.v10.i4.1140. PMID: 35211548; PMCID: PMC8855202.
29. Dawood DRM, Salum GM, El-Meguid MA. The Impact of COVID-19 on Liver Injury. Am J Med Sci. 2022; 363(2):94-103. doi: 10.1016/j.amjms.2021.11.001. PMID: 34752738; PMCID: PMC8571104.
30. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–62. https://doi.org/10.1016/s0140-6736(20)30566-3
31. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - Journal of the American Medical Association. 2020; Vol. 323: 1239–1242. https://doi.org/10.1001/jama.2020.2648
32. Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv [Internet]. 2020; 1–12. https://doi.org/10.1101/2020.03.25.20043133
33. Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: A systematic review. Diabetes Metab Syndr. 2020; 14(4):655-659. doi: 10.1016/j.dsx.2020.05.020. PMID: 32438328; PMCID: PMC7217103.
34. Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. Obesity. 2020; 28(6):1005. doi: 10.1002/oby.22818. PMID: 32237206.
35. De la Cruz-Cano E, Jiménez-González CDC, Díaz-Gandarilla JA, López-Victorio CJ, Escobar-Ramírez A, Uribe-López SA, Huerta-García E, Ayala-Sumuano JT, Morales-García V, Gútierrez-López L, González-Garrido JA. Comorbidities and laboratory parameters associated with SARS-CoV-2 infection severity in patients from the southeast of Mexico: a cross-sectional study. F1000Res. 2022; 11:10. doi: 10.12688/f1000research.74023.2. PMID: 35464048; PMCID: PMC9005987.
36. Tenorio-Mucha J, Hurtado-Roca Y. Revisión sobre obesidad como factor de riesgo para mortalidad por COVID-19. Acta Medica Peru. 2020; 37(3):324–329. http://dx.doi.org/10.35663/amp.2020.373.1197
37. Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care. 2020; 58:29–33. https://doi.org/10.1016/j.jcrc.2020.04.004
38. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514–523. https://doi.org/10.1016/s0140-6736(20)30154-9
39. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020; 395(10239):1763-70. doi: 10.1016/S0140-6736(20)31189-2.
40. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. https://doi.org/10.1016/s0140-6736(20)30183-5
41. Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020; 368:m606. https://doi.org/10.1136/bmj.m606
42. Kammar-García A, Vidal-Mayo J de J, Vera-Zertuche JM, Lazcano- Hernández M, Vera-López O, Segura-Badilla O, et al. Impact of comorbidities in mexican SARS-CoV-2 positive patients: a retrospective analysis in a national cohort. Rev Investig Clin. 2020;72(3):151-8. doi: 10.24875/RIC.20000207.
43. Palmieri L, Vanacore N, Donfrancesco C, Noce C Lo, Canevelli M, Punzo O, et al. Clinical characteristics of hospitalized individual dying with COVID-19 by age group in Italy. J Gerontol A Biol Sci Med Sci. 2020;XX:1-5. doi: 10.1093/gerona/glaa146.
44. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061–1069. Disponible en: 10.1001/jama.2020.1585
45. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020; Vol. 58: 1063–1069. https://doi.org/10.1515/cclm-2020-0240
46. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020; Vol. 141: 1648–1655. https://doi.org/10.1161/circulationaha.120.046941
47. Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a Disease. Med Clin North Am; 2018; Vol. 102: 13–33. https://doi.org/10.1016/j.mcna.2017.08.004
48. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Severe Obesity as an Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50. Obesity. 2020;2 8(9):1595-9. doi: 10.1002/oby.22913.
49. Petrova D, Salamanca-Fernández E, Rodríguez Barranco M, Navarro Pérez P, Jiménez Moleón JJ, Sánchez MJ. Obesity as a risk factor in COVID-19: Possible mechanisms and implications. Aten Primaria. 2020; 52(7):496–500. https://dx.doi.org/10.1016%2Fj.aprim.2020.05.003
50. Rosero RJ, Polanco JP, Sánchez P, Hernández E, Pinzón JB, Lizcano F. Obesidad: un problema en la atención de COVID-19. Rev Repert Med y Cirugía. 2020; 10–4. Available from: 10.31260/RepertMedCir.01217372.1035
51. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018; Vol. 6. https://doi.org/10.1186/s40425-018-0343-9
52. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020; 382(6):545–553. https://doi.org/10.1056/nejmoa1910607
53. Wang W, Liu X, Wu S, Chen S, Li Y, Nong L, et al. Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients with Pneumonia: Analysis of Disease Characteristics. J Infect Dis. 2020; 222(9):1444–1451. https://doi.org/10.1101/2020.02.26.20026989
54. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5): 2620–2629. https://doi.org/10.1172/jci137244
55. Rakotoarivelo V, Variya B, Langlois MF, Ramanathan S. Chemokines in human obesity. Cytokine. 2020; 127:154953. doi: 10.1016/j.cyto.2019.154953. PMID: 31865065.
56. Moreno-Fernandez J, Ochoa J, Ojeda ML, Nogales F, Carreras O, Díaz-Castro J. Inflammation and oxidative stress, the links between obesity and COVID-19: a narrative review. J Physiol Biochem. 2022; 22:1–11. doi: 10.1007/s13105-022-00887-4. PMID: 35316507; PMCID: PMC8938224.
57. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; Vol. 109: 531–538. https://doi.org/10.1007/s00392-020-01626-9
58. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia. Mil Med Res. 2020; Vol. 7. https://doi.org/10.1186/s40779-020-0233-6
59. Liu K, Wang X, Song G. Association of epicardial adipose tissue with the severity and adverse clinical outcomes of COVID-19: A meta-analysis. Int J Infect Dis. 2022; 120:33-40. doi: 10.1016/j.ijid.2022.04.013. PMID: 35421580; PMCID: PMC8996473.
60. Kwok S, Adam S, Ho JH, Iqbal Z, Turkington P, Razvi S, Le Roux CW, Soran H, Syed AA. Obesity: A critical risk factor in the COVID-19 pandemic. Clin Obes. 2020; 10(6):e12403. doi: 10.1111/cob.12403. PMID: 32857454; PMCID: PMC7460880.
61. Dongiovanni P, Meroni M, Longo M, Fracanzani AL. MAFLD in COVID-19 patients: an insidious enemy. Expert Rev Gastroenterol Hepatol. 2020; 14(10):867-872. doi: 10.1080/17474124.2020.1801417. PMID: 32705906.
1. 64. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020; Vol. 318: E736–41. https://doi.org/10.1152/ajpendo.00124.2020
2. 65. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020; 55:102763. doi: 10.1016/j.ebiom.2020.102763. PMID: 32361250; PMCID: PMC7165294.
3. 66. Rubio Herrera MA, Bretón Lesmes I. Obesidad en tiempos de COVID-19. Un desafío de salud global. Endocrinol Diabetes y Nutr. 2021; 68(2):123–129. Available from: https://www.elsevier.es/es-revista-endocrinologia-diabetes-nutricion-13-articulo-obesidad-tiempos-COVID-19-un-desafio-S2530016420302123
4. 67. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020; 142(1):68-78. doi: 10.1161/CIRCULATIONAHA.120.047549. PMID: 32293910.
5. 69. Gutata D, Alemu ZA. Factors Associated for COVID19 Severity Among Patients Treated at Selgalu Treatment Center Assosa in Ethiopia: A Case-Control Study. Int J Gen Med. 2022; 15:3303-3313. doi: 10.2147/IJGM.S351125. PMID: 35355795; PMCID: PMC8959867.
6. 70. Fadl N, Ali E, Salem TZ. COVID-19: Risk Factors Associated with Infectivity and Severity. Scand J Immunol. 2021; 93(6):e13039. doi: 10.1111/sji.13039. PMID: 33710663; PMCID: PMC8265317.
7. 71. Ramkissoon R, Wang XJ. The Impact of COVID-19 in Gastroenterology and Hepatology. J Clin Gastroenterol. 2021; 55(9):757-765. doi: 10.1097/MCG.0000000000001600. PMID: 34420001; PMCID: PMC8409901.
8. 72. Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020; 26(19):2323-2332. doi: 10.3748/wjg.v26.i19.2323. PMID: 32476796; PMCID: PMC7243653.
9. 73. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020; 31(6):1068-1077.e3. https://doi.org/10.1016/j.cmet.2020.04.021
10. 74. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Eur J Allergy Clin Immunol. 2020; 75(7):1730–1741. https://doi.org/10.1111/all.14238
11. 75. Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J, et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS One. 2020; 15(7 July). https://doi.org/10.1371/journal.pone.0235458
12. 76. Abad-García MF. El plagio y las revistas depredadoras como amenaza a la integridad científica. Anales de Pediatría. 2019; Volume 90 (1):57.e1-57.e8J2021; 57:21-34. Doi: https://doi.org/10.1016/j.anpedi.2018.11.003
13. 77. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
14. 78. Moriconi D, Masi S, Rebelos E, Virdis A, Manca ML, De Marco S, et al. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding. Obes Res Clin Pract. 2020; 14(3):205–209. https://doi.org/10.1016/j.orcp.2020.05.009
15. 79. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020; Vol. 71: 896–897. https://doi.org/10.1093/cid/ciaa415
16. 81. Huang JF, Wang XB, Zheng KI, Liu WY, Chen JJ, George J, et al. Obesity hypoventilation syndrome and severe COVID-19. Metabolism: Clinical and Experimental. 2020; Vol. 108. https://doi.org/10.1016/j.metabol.2020.154249
17. 82. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A, Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J Clin Endocrinol Metab. 2020; 105(8). https://doi.org/10.1210/clinem/dgaa346
18. 83. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020; 6(10):1192–1198. https://doi.org/10.1016/j.eng.2020.03.007
19. 84. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. Ann Intern Med. 2020; 173(10):773–781. https://doi.org/10.7326/m20-3742
20. 85. Hajifathalian K, Kumar S, Newberry C, Shah S, Fortune B, Krisko T, et al. Obesity is Associated with Worse Outcomes in COVID-19: Analysis of Early Data from New York City. Obesity. 2020; 28(9):1606–12. https://doi.org/10.1002/oby.22923
21. 86. Wang J, Zhu L, Liu L, Zhao X an, Zhang Z, Xue L, et al. Overweight and Obesity are Risk Factors of Severe Illness in Patients with COVID-19. Obesity. 2020; 28(11):2049–2055. https://doi.org/10.1002/oby.22979
22. 87. Steinberg E, Wright E, Kushner B. In young adults with COVID-19, obesity is associated with adverse outcomes. West J Emerg Med. 2020;21(4):752–755. https://doi.org/10.5811/westjem.2020.5.47972
23. 88. Kang L, Li Y, Hu S, Chen M, Yang C, Yang BX, et al. The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus. Lancet Psychiatry; 2020; Vol. 7:e14. https://doi.org/10.1016/s2215-0366(20)30047-x
24. 89. Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: A retrospective study. Chin Med J. 2020; 133(11):1261–1267. Disponible en: https://journals.lww.com/cmj/Fulltext/2020/06050/Clinical_characteristics_of_fatal_and_recovered.1.aspx
25. 90. Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, Liu WY, George J, Zheng MH. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. doi: 10.1016/j.metabol.2020.154244. PMID: 32320741; PMCID: PMC7166301.
26. 91. Wijarnpreecha K, Ungprasert P, Panjawatanan P, Harnois DM, Zaver HB, Ahmed A, Kim D. COVID-19 and liver injury: a meta-analysis. Eur J Gastroenterol Hepatol. 2021; 33(7):990-995. doi: 10.1097/MEG.0000000000001817. PMID: 32639420; PMCID: PMC8162043.
27. 92. Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, Tongji Multidisciplinary Team for Treating COVID-19 (TTTC) Eta al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2021; 74(6):1295-1302. doi: 10.1016/j.jhep.2020.12.012. PMID: 33347952; PMCID: PMC7749734.
28. 93. Pott-Junior H, Bittencourt NQP, Chacha SFG, Luporini RL, Cominetti MR, Anibal FF. Elevations in Liver Transaminases in COVID-19: (How) Are They Related? Front Med. 2021; 8:705247. doi: 10.3389/fmed.2021.705247. PMID: 34336904; PMCID: PMC8319468.
29. 94. Campos-Varela I, Villagrasa A, Simon-Talero M, Riveiro-Barciela M, Ventura-Cots M, Aguilera-Castro L, Et al. The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. Therap Adv Gastroenterol. 2021; 14:17562848211016567. doi: 10.1177/17562848211016567. PMID: 34104210; PMCID: PMC8170328.
30. 95. Signorello A, Lenci I, Milana M, Grassi G, Baiocchi L. COVID-19 in normal, diseased and transplanted liver. World J Gastroenterol. 2021; 27(20):2576-2585. doi: 10.3748/wjg.v27.i20.2576. PMID: 34092976; PMCID: PMC8160629.
31. 96. Badedi M, Darraj H, Alnami AQ, Makrami A, Mahfouz MS, Alhazmi K, Mahmoud N, Mosa H. Epidemiological and Clinical Characteristics of Deceased COVID-19 Patients. Int J Gen Med. 2021; 14:3809-3819. doi: 10.2147/IJGM.S320713. PMID: 34335047; PMCID: PMC8317935.
32. 97. Lazova S, Alexandrova T, Gorelyova-Stefanova N, Atanasov K, Tzotcheva I, Velikova T. Liver Involvement in Children with COVID-19 and Multisystem Inflammatory Syndrome: A Single-Center Bulgarian Observational Study. Microorganisms. 2021; 9(9):1958. doi: 10.3390/microorganisms9091958. PMID: 34576853; PMCID: PMC8467138.
33. 98. Valenzise M, D'Amico F, Cucinotta U, Lugarà C, Zirilli G, Zema A, Wasniewska M, Pajno GB. The lockdown effects on a pediatric obese population in the COVID-19 era. Ital J Pediatr. 2021; 47(1):209. doi: 10.1186/s13052-021-01142-0. PMID: 34663397; PMCID: PMC8521262.
34. 99. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966. PMID: 32444366; PMCID: PMC7243801.
35. 100. Yang J, Ma Z, Lei Y. A meta-analysis of the association between obesity and COVID-19. Epidemiol Infect. 2020;149:e11. doi: 10.1017/S0950268820003027. PMID: 33349290; PMCID: PMC7844214.
36. 101. Vidal-Cevallos P, Higuera-De-La-Tijera F, Chávez-Tapia NC, Sanchez-Giron F, Cerda-Reyes E, Rosales-Salyano VH, Servin-Caamaño A, Vázquez-Medina MU, Méndez-Sánchez N. Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study. Ann Hepatol. 2021; 24:100338. doi: 10.1016/j.aohep.2021.100338. PMID: 33647501; PMCID: PMC7908830.
37. 102. Sanoudou D, Hill MA, Belanger MJ, Arao K, Mantzoros CS. Obesity, metabolic phenotypes and COVID-19. Metabolism. 2022; 128:155121. doi: 10.1016/j.metabol.2021.155121. PMID: 35026232; PMCID: PMC8743503.
38. 103. Michalakis K, Ilias I. SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects. Diabetes Metab Syndr. 2020; 14(4):469-471. doi: 10.1016/j.dsx.2020.04.033. PMID: 32387864; PMCID: PMC7189186.
39. 104. van der Voort PHJ, Moser J, Zandstra DF, Muller Kobold AC, Knoester M, Calkhoven CF, Hamming I, van Meurs M. Leptin levels in SARS-CoV-2 infection related respiratory failure: A cross-sectional study and a pathophysiological framework on the role of fat tissue. Heliyon. 2020; 6(8):e04696. doi: 10.1016/j.heliyon.2020.e04696. PMID: 32844126; PMCID: PMC7439829.
40. 105. Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020 Jun;16(6):297-298. doi: 10.1038/s41574-020-0353-9. PMID: 32242089; PMCID: PMC7113912.
2. Gargallo Vaamonde JG, Álvarez-Món MA. Obesidad y sobrepeso. Med - Programa Form Médica Contin Acreditado. 2020; 13(14):767–776. https://doi.org/10.1016/j.med.2020.07.010
3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
4. Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thursz MR, Nayagam S, Manousou P. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020; 15(10):e0240400. doi: 10.1371/journal.pone.0240400. PMID: 33031439; PMCID: PMC7544083.
5. Padilla Machaca PM, Cárdenas Ramírez BE, Cabrera Cabrejos MC. Impacto del COVID-19 en las enfermedades hepáticas y la salud pública en el Perú [Internet]. Vol. 40, Rev gastroenterol Peru. 2020; 40(2): 162–172. Available from: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1144655
6. López LE, Mazzucco MD. Alteraciones de parámetros de laboratorio en pacientes con SARS-CoV-2. Acta bioquímica clínica latinoamericana. 2020; Vol. 54 (3): 293–307. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-29572020000300006&lang=pt%0Ahttp://www.scielo.org.ar/pdf/abcl/v54n3/v54n3a06.pdf
7. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020; Vol. 40 (5): 998–1004. https://doi.org/10.1111/liv.14435
8. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63(3):364–374. https://doi.org/10.1007/s11427-020-1643-8
9. Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, Deng Y, Wei S. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(0):E005. Chinese. doi: 10.3760/cma.j.issn.1001-0939.2020.0005. PMID: 32026671.
10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507–513. https://doi.org/10.1016/s0140-6736(20)30211-7
11. Organización Mundial de la Salud/Organización Panamericana de la Salud. COVID-19 en Ecuador - OPS/OMS. 2021 [cited 2022 Apr 13]. Available from: https://www.paho.org/es/ecuador
12. Encuesta Nacional de Salud y Nutrición. 2018. Ecuador. La obesidad complica aún más los cuadros de pacientes con COVID-19. Estadisticas sociodemográficas. Disponible en: https://anda.inec.gob.ec/anda/index.php/catalog/891
13. Gonzalo Callejón MG, Caballero Villarraso J, Bobillo Lobato J, Díaz Portillo J. Contribuciones analíticas para el estudio de pacientes con infección COVID-19. Soc Andaluza Análisis Clínicos y Med Lab. 2020; (5):1–29. Disponible en: https://www.sanac.org/images/site/covid2019/2020_Callejon_y_cols_Contribuciones_analiticas.pdf
14. Nogueira-de Almeida CA, Del Ciampo LA, Ferraz IS, Del Ciampo IRL, Contini AA, Ued F da V. COVID-19 and obesity in childhood and adolescence: a clinical review. J Pediatr. 2020; Vol. 96: 546–558. https://doi.org/10.1016/j.jped.2020.07.001
15. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol. 2020; 18(7):1561-1566. doi: 10.1016/j.cgh.2020.04.002. PMID: 32283325; PMCID: PMC7194865.
16. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain M; LICORN and the Lille COVID-19 and Obesity study group. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity. 2020; 28(7):1195-1199. doi: 10.1002/oby.22831. Erratum in: Obesity (Silver Spring). 2020 Oct;28(10):1994. PMID: 32271993; PMCID: PMC7262326.
17. Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metab Syndr. 2020;14 (5):825-827. doi: 10.1016/j.dsx.2020.06.013. PMID: 32540736; PMCID: PMC7834636.
18. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, Mylonakis E. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity. 2020; 28(7):1200-1204. doi: 10.1002/oby.22859. PMID: 32352637; PMCID: PMC7267224.
19. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver Int. 2020; 40(6):1321-1326. doi: 10.1111/liv.14449. PMID: 32239591; PMCID: PMC7228333.
20. Deng M, Qi Y, Deng L, Wang H, Xu Y, Li Z, Meng Z, Tang J, Dai Z. Obesity as a Potential Predictor of Disease Severity in Young COVID-19 Patients: A Retrospective Study. Obesity. 2020; 28(10):1815-1825. doi: 10.1002/oby.22943. PMID: 32602202; PMCID: PMC7361308.
21. Chang TH, Chou CC, Chang LY. Effect of obesity and body mass index on coronavirus disease 2019 severity: A systematic review and meta-analysis. Obes Rev. 2020; 21(11):e13089. doi: 10.1111/obr.13089. PMID: 32929833.
22. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: A systematic review and meta-analysis. J Med Virol. 2021; 93(1):257-261. doi: 10.1002/jmv.26237. PMID: 32603481; PMCID: PMC7361606.
23. Perez A, Cantor A, Rudolph B, Miller J, Kogan-Liberman D, Gao Q, Da Silva B, Margolis KG, Ovchinsky N, Martinez M. Liver involvement in children with SARS-COV-2 infection: Two distinct clinical phenotypes caused by the same virus. Liver Int. 2021; 41(9):2068-2075. doi: 10.1111/liv.14887. PMID: 33826804; PMCID: PMC8251417.
24. Krishnan A, Prichett L, Tao X, Alqahtani SA, Hamilton JP, Mezey E, Strauss AT, Kim A, Potter JJ, Chen PH, Woreta TA. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World J Gastroenterol. 2022; 28(5):570-587. doi: 10.3748/wjg.v28.i5.570. PMID: 35316959; PMCID: PMC8905016.
25. Russo A, Pisaturo M, Palladino R, Maggi P, Numis FG, Gentile I, Et al. On Behalf Of CoviCam Group. Prognostic Value of Transaminases and Bilirubin Levels at Admission to Hospital on Disease Progression and Mortality in Patients with COVID-19- An Observational Retrospective Study. Pathogens. 2022;11(6):652. doi: 10.3390/pathogens11060652. PMID: 35745506; PMCID: PMC9227474.
26. Elnaggar M, Abomhya A, Elkhattib I, Dawoud N, Doshi R. COVID-19 and liver diseases, what we know so far. World J Clin Cases. 2022;10(13):3969-3980. doi: 10.12998/wjcc.v10.i13.3969. PMID: 35665122; PMCID: PMC9131221.
27. Siddiqui MA, Suresh S, Simmer S, Abu-Ghanimeh M, Karrick M, Nimri F, Musleh M, Mediratta V, Al-Shammari M, Russell S, Jou J, Dang D, Salgia R, Zuchelli T. Increased Morbidity and Mortality in COVID-19 Patients with Liver Injury. Dig Dis Sci. 2022; 67(6):2577-2583. doi: 10.1007/s10620-021-07007-0. PMID: 33945064; PMCID: PMC8094979.
28. Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases. 2022; 10(4):1140-1163. doi: 10.12998/wjcc.v10.i4.1140. PMID: 35211548; PMCID: PMC8855202.
29. Dawood DRM, Salum GM, El-Meguid MA. The Impact of COVID-19 on Liver Injury. Am J Med Sci. 2022; 363(2):94-103. doi: 10.1016/j.amjms.2021.11.001. PMID: 34752738; PMCID: PMC8571104.
30. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–62. https://doi.org/10.1016/s0140-6736(20)30566-3
31. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - Journal of the American Medical Association. 2020; Vol. 323: 1239–1242. https://doi.org/10.1001/jama.2020.2648
32. Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv [Internet]. 2020; 1–12. https://doi.org/10.1101/2020.03.25.20043133
33. Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: A systematic review. Diabetes Metab Syndr. 2020; 14(4):655-659. doi: 10.1016/j.dsx.2020.05.020. PMID: 32438328; PMCID: PMC7217103.
34. Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. Obesity. 2020; 28(6):1005. doi: 10.1002/oby.22818. PMID: 32237206.
35. De la Cruz-Cano E, Jiménez-González CDC, Díaz-Gandarilla JA, López-Victorio CJ, Escobar-Ramírez A, Uribe-López SA, Huerta-García E, Ayala-Sumuano JT, Morales-García V, Gútierrez-López L, González-Garrido JA. Comorbidities and laboratory parameters associated with SARS-CoV-2 infection severity in patients from the southeast of Mexico: a cross-sectional study. F1000Res. 2022; 11:10. doi: 10.12688/f1000research.74023.2. PMID: 35464048; PMCID: PMC9005987.
36. Tenorio-Mucha J, Hurtado-Roca Y. Revisión sobre obesidad como factor de riesgo para mortalidad por COVID-19. Acta Medica Peru. 2020; 37(3):324–329. http://dx.doi.org/10.35663/amp.2020.373.1197
37. Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care. 2020; 58:29–33. https://doi.org/10.1016/j.jcrc.2020.04.004
38. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514–523. https://doi.org/10.1016/s0140-6736(20)30154-9
39. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020; 395(10239):1763-70. doi: 10.1016/S0140-6736(20)31189-2.
40. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. https://doi.org/10.1016/s0140-6736(20)30183-5
41. Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020; 368:m606. https://doi.org/10.1136/bmj.m606
42. Kammar-García A, Vidal-Mayo J de J, Vera-Zertuche JM, Lazcano- Hernández M, Vera-López O, Segura-Badilla O, et al. Impact of comorbidities in mexican SARS-CoV-2 positive patients: a retrospective analysis in a national cohort. Rev Investig Clin. 2020;72(3):151-8. doi: 10.24875/RIC.20000207.
43. Palmieri L, Vanacore N, Donfrancesco C, Noce C Lo, Canevelli M, Punzo O, et al. Clinical characteristics of hospitalized individual dying with COVID-19 by age group in Italy. J Gerontol A Biol Sci Med Sci. 2020;XX:1-5. doi: 10.1093/gerona/glaa146.
44. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061–1069. Disponible en: 10.1001/jama.2020.1585
45. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020; Vol. 58: 1063–1069. https://doi.org/10.1515/cclm-2020-0240
46. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020; Vol. 141: 1648–1655. https://doi.org/10.1161/circulationaha.120.046941
47. Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a Disease. Med Clin North Am; 2018; Vol. 102: 13–33. https://doi.org/10.1016/j.mcna.2017.08.004
48. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Severe Obesity as an Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50. Obesity. 2020;2 8(9):1595-9. doi: 10.1002/oby.22913.
49. Petrova D, Salamanca-Fernández E, Rodríguez Barranco M, Navarro Pérez P, Jiménez Moleón JJ, Sánchez MJ. Obesity as a risk factor in COVID-19: Possible mechanisms and implications. Aten Primaria. 2020; 52(7):496–500. https://dx.doi.org/10.1016%2Fj.aprim.2020.05.003
50. Rosero RJ, Polanco JP, Sánchez P, Hernández E, Pinzón JB, Lizcano F. Obesidad: un problema en la atención de COVID-19. Rev Repert Med y Cirugía. 2020; 10–4. Available from: 10.31260/RepertMedCir.01217372.1035
51. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018; Vol. 6. https://doi.org/10.1186/s40425-018-0343-9
52. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020; 382(6):545–553. https://doi.org/10.1056/nejmoa1910607
53. Wang W, Liu X, Wu S, Chen S, Li Y, Nong L, et al. Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients with Pneumonia: Analysis of Disease Characteristics. J Infect Dis. 2020; 222(9):1444–1451. https://doi.org/10.1101/2020.02.26.20026989
54. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5): 2620–2629. https://doi.org/10.1172/jci137244
55. Rakotoarivelo V, Variya B, Langlois MF, Ramanathan S. Chemokines in human obesity. Cytokine. 2020; 127:154953. doi: 10.1016/j.cyto.2019.154953. PMID: 31865065.
56. Moreno-Fernandez J, Ochoa J, Ojeda ML, Nogales F, Carreras O, Díaz-Castro J. Inflammation and oxidative stress, the links between obesity and COVID-19: a narrative review. J Physiol Biochem. 2022; 22:1–11. doi: 10.1007/s13105-022-00887-4. PMID: 35316507; PMCID: PMC8938224.
57. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; Vol. 109: 531–538. https://doi.org/10.1007/s00392-020-01626-9
58. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia. Mil Med Res. 2020; Vol. 7. https://doi.org/10.1186/s40779-020-0233-6
59. Liu K, Wang X, Song G. Association of epicardial adipose tissue with the severity and adverse clinical outcomes of COVID-19: A meta-analysis. Int J Infect Dis. 2022; 120:33-40. doi: 10.1016/j.ijid.2022.04.013. PMID: 35421580; PMCID: PMC8996473.
60. Kwok S, Adam S, Ho JH, Iqbal Z, Turkington P, Razvi S, Le Roux CW, Soran H, Syed AA. Obesity: A critical risk factor in the COVID-19 pandemic. Clin Obes. 2020; 10(6):e12403. doi: 10.1111/cob.12403. PMID: 32857454; PMCID: PMC7460880.
61. Dongiovanni P, Meroni M, Longo M, Fracanzani AL. MAFLD in COVID-19 patients: an insidious enemy. Expert Rev Gastroenterol Hepatol. 2020; 14(10):867-872. doi: 10.1080/17474124.2020.1801417. PMID: 32705906.
1. 64. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020; Vol. 318: E736–41. https://doi.org/10.1152/ajpendo.00124.2020
2. 65. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020; 55:102763. doi: 10.1016/j.ebiom.2020.102763. PMID: 32361250; PMCID: PMC7165294.
3. 66. Rubio Herrera MA, Bretón Lesmes I. Obesidad en tiempos de COVID-19. Un desafío de salud global. Endocrinol Diabetes y Nutr. 2021; 68(2):123–129. Available from: https://www.elsevier.es/es-revista-endocrinologia-diabetes-nutricion-13-articulo-obesidad-tiempos-COVID-19-un-desafio-S2530016420302123
4. 67. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020; 142(1):68-78. doi: 10.1161/CIRCULATIONAHA.120.047549. PMID: 32293910.
5. 69. Gutata D, Alemu ZA. Factors Associated for COVID19 Severity Among Patients Treated at Selgalu Treatment Center Assosa in Ethiopia: A Case-Control Study. Int J Gen Med. 2022; 15:3303-3313. doi: 10.2147/IJGM.S351125. PMID: 35355795; PMCID: PMC8959867.
6. 70. Fadl N, Ali E, Salem TZ. COVID-19: Risk Factors Associated with Infectivity and Severity. Scand J Immunol. 2021; 93(6):e13039. doi: 10.1111/sji.13039. PMID: 33710663; PMCID: PMC8265317.
7. 71. Ramkissoon R, Wang XJ. The Impact of COVID-19 in Gastroenterology and Hepatology. J Clin Gastroenterol. 2021; 55(9):757-765. doi: 10.1097/MCG.0000000000001600. PMID: 34420001; PMCID: PMC8409901.
8. 72. Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020; 26(19):2323-2332. doi: 10.3748/wjg.v26.i19.2323. PMID: 32476796; PMCID: PMC7243653.
9. 73. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020; 31(6):1068-1077.e3. https://doi.org/10.1016/j.cmet.2020.04.021
10. 74. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Eur J Allergy Clin Immunol. 2020; 75(7):1730–1741. https://doi.org/10.1111/all.14238
11. 75. Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J, et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS One. 2020; 15(7 July). https://doi.org/10.1371/journal.pone.0235458
12. 76. Abad-García MF. El plagio y las revistas depredadoras como amenaza a la integridad científica. Anales de Pediatría. 2019; Volume 90 (1):57.e1-57.e8J2021; 57:21-34. Doi: https://doi.org/10.1016/j.anpedi.2018.11.003
13. 77. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
14. 78. Moriconi D, Masi S, Rebelos E, Virdis A, Manca ML, De Marco S, et al. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding. Obes Res Clin Pract. 2020; 14(3):205–209. https://doi.org/10.1016/j.orcp.2020.05.009
15. 79. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020; Vol. 71: 896–897. https://doi.org/10.1093/cid/ciaa415
16. 81. Huang JF, Wang XB, Zheng KI, Liu WY, Chen JJ, George J, et al. Obesity hypoventilation syndrome and severe COVID-19. Metabolism: Clinical and Experimental. 2020; Vol. 108. https://doi.org/10.1016/j.metabol.2020.154249
17. 82. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A, Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J Clin Endocrinol Metab. 2020; 105(8). https://doi.org/10.1210/clinem/dgaa346
18. 83. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020; 6(10):1192–1198. https://doi.org/10.1016/j.eng.2020.03.007
19. 84. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. Ann Intern Med. 2020; 173(10):773–781. https://doi.org/10.7326/m20-3742
20. 85. Hajifathalian K, Kumar S, Newberry C, Shah S, Fortune B, Krisko T, et al. Obesity is Associated with Worse Outcomes in COVID-19: Analysis of Early Data from New York City. Obesity. 2020; 28(9):1606–12. https://doi.org/10.1002/oby.22923
21. 86. Wang J, Zhu L, Liu L, Zhao X an, Zhang Z, Xue L, et al. Overweight and Obesity are Risk Factors of Severe Illness in Patients with COVID-19. Obesity. 2020; 28(11):2049–2055. https://doi.org/10.1002/oby.22979
22. 87. Steinberg E, Wright E, Kushner B. In young adults with COVID-19, obesity is associated with adverse outcomes. West J Emerg Med. 2020;21(4):752–755. https://doi.org/10.5811/westjem.2020.5.47972
23. 88. Kang L, Li Y, Hu S, Chen M, Yang C, Yang BX, et al. The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus. Lancet Psychiatry; 2020; Vol. 7:e14. https://doi.org/10.1016/s2215-0366(20)30047-x
24. 89. Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: A retrospective study. Chin Med J. 2020; 133(11):1261–1267. Disponible en: https://journals.lww.com/cmj/Fulltext/2020/06050/Clinical_characteristics_of_fatal_and_recovered.1.aspx
25. 90. Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, Liu WY, George J, Zheng MH. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. doi: 10.1016/j.metabol.2020.154244. PMID: 32320741; PMCID: PMC7166301.
26. 91. Wijarnpreecha K, Ungprasert P, Panjawatanan P, Harnois DM, Zaver HB, Ahmed A, Kim D. COVID-19 and liver injury: a meta-analysis. Eur J Gastroenterol Hepatol. 2021; 33(7):990-995. doi: 10.1097/MEG.0000000000001817. PMID: 32639420; PMCID: PMC8162043.
27. 92. Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, Tongji Multidisciplinary Team for Treating COVID-19 (TTTC) Eta al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2021; 74(6):1295-1302. doi: 10.1016/j.jhep.2020.12.012. PMID: 33347952; PMCID: PMC7749734.
28. 93. Pott-Junior H, Bittencourt NQP, Chacha SFG, Luporini RL, Cominetti MR, Anibal FF. Elevations in Liver Transaminases in COVID-19: (How) Are They Related? Front Med. 2021; 8:705247. doi: 10.3389/fmed.2021.705247. PMID: 34336904; PMCID: PMC8319468.
29. 94. Campos-Varela I, Villagrasa A, Simon-Talero M, Riveiro-Barciela M, Ventura-Cots M, Aguilera-Castro L, Et al. The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. Therap Adv Gastroenterol. 2021; 14:17562848211016567. doi: 10.1177/17562848211016567. PMID: 34104210; PMCID: PMC8170328.
30. 95. Signorello A, Lenci I, Milana M, Grassi G, Baiocchi L. COVID-19 in normal, diseased and transplanted liver. World J Gastroenterol. 2021; 27(20):2576-2585. doi: 10.3748/wjg.v27.i20.2576. PMID: 34092976; PMCID: PMC8160629.
31. 96. Badedi M, Darraj H, Alnami AQ, Makrami A, Mahfouz MS, Alhazmi K, Mahmoud N, Mosa H. Epidemiological and Clinical Characteristics of Deceased COVID-19 Patients. Int J Gen Med. 2021; 14:3809-3819. doi: 10.2147/IJGM.S320713. PMID: 34335047; PMCID: PMC8317935.
32. 97. Lazova S, Alexandrova T, Gorelyova-Stefanova N, Atanasov K, Tzotcheva I, Velikova T. Liver Involvement in Children with COVID-19 and Multisystem Inflammatory Syndrome: A Single-Center Bulgarian Observational Study. Microorganisms. 2021; 9(9):1958. doi: 10.3390/microorganisms9091958. PMID: 34576853; PMCID: PMC8467138.
33. 98. Valenzise M, D'Amico F, Cucinotta U, Lugarà C, Zirilli G, Zema A, Wasniewska M, Pajno GB. The lockdown effects on a pediatric obese population in the COVID-19 era. Ital J Pediatr. 2021; 47(1):209. doi: 10.1186/s13052-021-01142-0. PMID: 34663397; PMCID: PMC8521262.
34. 99. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966. PMID: 32444366; PMCID: PMC7243801.
35. 100. Yang J, Ma Z, Lei Y. A meta-analysis of the association between obesity and COVID-19. Epidemiol Infect. 2020;149:e11. doi: 10.1017/S0950268820003027. PMID: 33349290; PMCID: PMC7844214.
36. 101. Vidal-Cevallos P, Higuera-De-La-Tijera F, Chávez-Tapia NC, Sanchez-Giron F, Cerda-Reyes E, Rosales-Salyano VH, Servin-Caamaño A, Vázquez-Medina MU, Méndez-Sánchez N. Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study. Ann Hepatol. 2021; 24:100338. doi: 10.1016/j.aohep.2021.100338. PMID: 33647501; PMCID: PMC7908830.
37. 102. Sanoudou D, Hill MA, Belanger MJ, Arao K, Mantzoros CS. Obesity, metabolic phenotypes and COVID-19. Metabolism. 2022; 128:155121. doi: 10.1016/j.metabol.2021.155121. PMID: 35026232; PMCID: PMC8743503.
38. 103. Michalakis K, Ilias I. SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects. Diabetes Metab Syndr. 2020; 14(4):469-471. doi: 10.1016/j.dsx.2020.04.033. PMID: 32387864; PMCID: PMC7189186.
39. 104. van der Voort PHJ, Moser J, Zandstra DF, Muller Kobold AC, Knoester M, Calkhoven CF, Hamming I, van Meurs M. Leptin levels in SARS-CoV-2 infection related respiratory failure: A cross-sectional study and a pathophysiological framework on the role of fat tissue. Heliyon. 2020; 6(8):e04696. doi: 10.1016/j.heliyon.2020.e04696. PMID: 32844126; PMCID: PMC7439829.
40. 105. Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020 Jun;16(6):297-298. doi: 10.1038/s41574-020-0353-9. PMID: 32242089; PMCID: PMC7113912.
Published
2022-11-26
How to Cite
Herlinda Virginia Ponce Espinoza, & Augusto Leonel Durán Cañarte. (2022). Concentraciones séricas de aminotransferasa y su asociación a la obesidad en pacientes hospitalizados por covid-19. Revista Cien´tifica FIPCAEC (Fomento De La investigación Y publicación En Ciencias Administrativas, Económicas Y Contables), 7(4), 2042-2075. Retrieved from https://fipcaec.com/index.php/fipcaec/article/view/719
Section
Artículos de Investigación
